$40.00 1.2%
APLS Stock Price vs. AI Score (Last 150 days)
Data gathered: July 16

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.


Apellis Pharmaceuticals
Price $40.00
Target Price Sign up
Volume 1,100,000
Market Cap $4.85B
Year Range $34.98 - $72.47
Dividend Yield 0%
Revenue per Employee $1,102,242
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '24172M137M35M-66M-71M-0.420
Q4 '23149M148M670,000-89M-84M-0.730
Q3 '23110M156M-46M-140M-148M-1.170
Q2 '2394M111M-17M-122M-115M-1.020
Q1 '2345M102M-57M-178M-170M-1.560

Insider Transactions View All

Dunlop A. Sinclair filed to sell 136,998 shares at $39.6.
June 21 '24
Dunlop A. Sinclair filed to sell 138,693 shares at $39.2.
June 21 '24
Deschatelets Pascal filed to sell 1,115,983 shares at $44.
May 9 '24
Deschatelets Pascal filed to sell 1,116,083 shares at $42.8.
May 9 '24
Deschatelets Pascal filed to sell 1,138,555 shares at $42.2.
May 9 '24

What is the Market Cap of Apellis Pharmaceuticals?

The Market Cap of Apellis Pharmaceuticals is $4.85B.

How Many People Work at Apellis Pharmaceuticals?

As of our latest update, Apellis Pharmaceuticals employed approximately 476 people worldwide. However, it's important to note that Apellis Pharmaceuticals' workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is Apellis Pharmaceuticals' revenue per employee?

$1,102,242. To calculate Apellis Pharmaceuticals' revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of Apellis Pharmaceuticals?

Currently, the price of one share of Apellis Pharmaceuticals stock is $40.00.

How can I analyze the APLS stock price chart for investment decisions?

The APLS stock price chart above provides a comprehensive visual representation of Apellis Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Apellis Pharmaceuticals shares. Our platform offers an up-to-date APLS stock price chart, along with technical data analysis and alternative data insights.

Does APLS offer dividends to its shareholders?

As of our latest update, Apellis Pharmaceuticals (APLS) does not offer dividends to its shareholders. Investors interested in Apellis Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Apellis Pharmaceuticals?

Some of the similar stocks of Apellis Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.